|Articles|April 1, 2016
- Pharmaceutical Executive-04-01-2016
- Volume 36
- Issue 4
Pharmaceutical Executive, April 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 10 years ago
Closing the Gaps in Drug Chain of Custodyover 10 years ago
Data Unleashed: Cooperation Among Competitorsover 10 years ago
Raising the Stakes On Value-Based Pricingover 10 years ago
The Diversity Dearth in Pharmaover 10 years ago
Information in Action: A Conversation with Barbara Lopez Kunzover 10 years ago
R&D Model Mixes Compassion, Calculationover 10 years ago
Pressure Builds to Revamp Off-Label Marketing Rulesover 10 years ago
Drug Compounding: A Cause and Cure for High Drug Prices?over 10 years ago
The Odd Coupleover 10 years ago
Country Report: EgyptAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
3
What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?
4
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
5